RU2358723C1 - Antiwithdrawal agent, biologically active additive, pharmaceutical composition, medical product and method of producing - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: new agent is characterised with antiwithdrawal action, containing L-serine and fructose as an active components and additionally tianin, at mass ratio of L-serine, tianin and fructose (12-18):(0.8-1.2):(40-60) respectively. It is preferentially to use L-tianin at mass ratio of L-serine, L-tianin and fructose as 15:1:50. Said agent can be used as the biological food additive. The invention also concerns a pharmaceutical composition, method of producing and a medical product based on the agent or pharmaceutical composition as tablets, capsules or injections in pharmaceutically acceptable package. The agent allows relieving the alcohol withdrawal caused by overuse, e.g. of products containing ethyl alcohol.

EFFECT: managed objective symptoms of hangover, alcohol-damaged sensory filtration and the muscle coordination processes.

5 cl, 4 dwg, 1 tbl, 3 ex

Description

The invention relates to a new agent with anti-hangover, dietary supplement, pharmaceutical composition, drug capable of attenuating alcohol hangover caused by excessive consumption of products containing ethyl alcohol.

Hangover syndrome affects about 50% of the population who consume alcohol in significant doses, which causes economic damage, since during this period there is a significant decrease in human performance [Smith, S.M .; Barnes, G.M. Signs and symptoms of hangover: prevalence and relationship to alcohol use in a general adult population. Drug Alcohol Depend. 11: 249-269; 1983]. So, for example, the economic damage associated with poor performance due to a hangover in the US in 2000 amounted to about $ 148 billion [Wiese, J.G .; Shiipak, M.G .; Browner, W.S. The alcohol hangover. Ann.Intern.Med. 132: 897-902; 2000]. The hangover syndrome develops within a few hours after the end of acute alcohol intoxication against the background of the restoration of general motor activity, thinking and memory [Streufert, S .; Pogash, R .; Braig, D .; Gingrich, D .; Kantner, A .; Landis, R .; Lonardi, L .; Roache, J .; Severs, W. Alcohol hangover and managerial effectiveness. Alcohol Clin. Exp. Res. 19: 1141-1146; 1995. Salimov, R.M .; Markina, N.V .; Perepelkina, O.V .; Maiskii, A.I .; Poletaeva, I.I. Rapid tolerance to ethanol and high voluntary alcohol consumption in mice selected for brain weight. Zh. Vyssh. Nerv. Deiat. Im I.P. Pavlova. 53: 100-106; 2003. Schwandt, M. L .; Barr, C. S .; Suomi, S.J .; Higley, J.D. Age-dependent variation in behavior following acute ethanol administration in male and female adolescent rhesus macaques (Macaca mulatta). Alcohol Clin. Exp. Res. 31: 228-237; 2007] and lasts from several hours to a day. A hangover condition is characterized by a complex set of subjective feelings of discomfort and impaired sensory-motor coordination, which are objectively recorded, in particular, as a violation of filtering sensory information in the brain [Grillon, Sinha, O'Malley, 1994; Grillon et al., 2000] and difficulty maintaining body balance. Violation of the filtration of sensory information and difficulty maintaining equilibrium have a homologous manifestation in humans and different types of mammals and can be measured in an animal experiment by evaluating prepulse inhibition of trembling in response to an acoustic stimulus [Maisky AI, Salimov P.M. Guidelines for preclinical evaluation of drugs for the treatment of alcoholism. Guidance on the experimental (preclinical) evaluation of new drugs. M .: Remedium, 2000, p. 172-175. Chester, J.A .; Barrenha, G. D. Acoustic startle at baseline and during acute alcohol withdrawal in replicate mouse lines selectively bred for high or low alcohol preference. Alcohol Clin. Exp. Res. 31: 1633-1644; 2007] and the ability to stay on a rotating rod [Nuzhny V.P., Demeshina I.V., Zabirova I.G., Listvina V.P., Lvova Yu.A., Samoilik L.V., Surkova L.A. Assessment of the severity of the post-toxic state provoked by acute alcohol intoxication in an animal experiment. News of science and technology VINITI. Series Medicine. Vol. Alcoholic disease, 2000. No. 7, p.1-6. York, J.L .; Regan, S.G. After-effects of acute alcohol intoxication. Alcohol 5: 403-407; 1988].

Known drug dimercaprol, which is an antidote for poisoning with arsenic compounds, heavy metal salts, cardiac glycosides, and also improves lipid peroxidation in the period after alcohol intoxication [US 20060148898 A1. Curing and prophylactic agent applied during the use of alcohol and psychoactive substances. 2006-07-06]. At the same time, the ability of dimercaprol to restore the processes of sensory filtration and muscle coordination disrupted by alcohol is not known. In addition, it is known that contraindications that limit the use of dimercaprol include liver failure and arterial hypertension [Drug Register. Dimercaprol, http://www.rlsnet.ru/mnn_dimerkaprol.html; U.S. Department of Health & Human Services. Dimercaprol, http://www.remm.nlm.gov/dimercaprol.htm]. These contraindications are of particular importance when using dimercaprol in combination with alcohol, which in turn creates an additional burden on the detoxifying function of the liver and can provoke arterial hypertension [Gorelick, P.V. Alcohol and stroke. Stroke. 18: 268-271; 1987; Tirapelli, C. R .; Leone, A.F .; Coelho, E. B. .; Resstel, L.B .; Correa, F.M .; Lanchote, V.L .; Uyemura, S.A .; Padovan, C. M .; de Oliveira, A.M. Effect of ethanol consumption on blood pressure and rat mesenteric arterial bed, aorta and carotid responsiveness. J. Pharm. Pharmacol 59: 985-993; 2007; Zhang, Y .; Venugopal, S.K .; He, S .; Liu, P .; Wu, J .; Zern, M.A. Ethanol induces apoptosis in hepatocytes by a pathway involving novel protein kinase C isoforms. Cell Signal. 19: 2339-2350; 2007].

It is known that the active ingredient contains succinic acid and / or its salts, fumaric acid and / or its salts, fructose, St. John's wort herb dry extract (Hypericum), magnesium ion sources and potassium ion sources, which, when used after alcohol, can increase the time retention of animals on a rotating rod, although its ability to improve sensory filtration is not shown [RU 2250778. Means that reduce the adverse effects of acute alcohol intoxication. 2004.02.26]. This product does not contain the amino acids tianin and serine.

Known is a tool containing extracts of various medicinal plants, fructose, vitamin B2 and vitamin C, which can reduce the subjective manifestations of a hangover, but this tool has not shown the ability to improve the objective symptoms of a hangover - processes of sensory filtration and muscle coordination disturbed by alcohol [KR 20010036048. Beverage composition for hangover cures. 2001-05-07]. This product does not contain the amino acids tianin and serine.

It is known an agent containing oligosaccharide, including fructose, and amino acids, including L-serine, which can reduce the subjective manifestations of a hangover, but the ability to improve objective symptoms of a hangover - sensory filtration and muscle coordination disturbed by alcohol [CA 2453159. A composition and uses therefor for combating hangover.

2003-01-23]. This product does not contain the amino acid tianin.

Known tool containing tianine, which, when taken with alcohol, accelerates the metabolism of alcohol and reduces the subjective manifestations of a hangover. However, its effectiveness in taking it after drinking alcohol is not known and the ability to improve the objective symptoms of a hangover — sensory filtration and muscle coordination processes disrupted by alcohol [US 2007213400. Alcohol-metabolism enhancing composition and ingesta containing the same. 2007-09-13].

The following are definitions of terms that are used in the description of this invention.

“Amino acid” means a natural amino acid or a non-natural amino acid, the meaning of the latter is defined in this section. Preferred amino acids are amino acids containing an α or β amino group. Examples of natural amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, tianine, threonine and cysteine.

"Biologically active additives (BAA)" means substances of natural origin (their concentrates, solutions, mixtures, etc.) or biologically active substances identical to them of synthetic, semi-synthetic or biotechnological origin and their analogues that do not contain drugs and are intended for use with food or regardless of its intake, as well as for introduction into food. Supplements are used to enrich the human diet and give it special preventive and health-improving properties. Traditionally, dietary supplements are divided into three main groups: nutraceuticals, eubiotics (probiotics) and parapharmaceuticals. Parapharmaceuticals mean dietary supplements used for prophylaxis, adjuvant therapy, and maintaining the physiological boundaries of the functional activity of organs and systems. Parapharmaceuticals are organic acids, bioflavonoids, biogenic amines, alkaloids, oligosaccharides, polynucleotides, etc. Parapharmaceuticals are able to increase the adaptive capacity of the body in extreme conditions.

“Medicinal substance” (medicinal substance, drug-substance) means a physiologically active substance of synthetic or other (biotechnological, plant, animal, microbial and other) origin, having pharmacological activity and is the active principle of the pharmaceutical composition used for the manufacture and manufacture of a medicinal product ( facilities).

“Medicinal product (preparation)” - a substance (or a mixture of substances in the form of a pharmaceutical composition), in the form of tablets, capsules of injections, ointments, and other finished forms, intended to restore, correct, or change the physiological functions in humans and animals, as well as for treatment and disease prevention, diagnosis, anesthesia, contraception, cosmetology and more.

A “therapeutic cocktail” is a simultaneously administered combination of two or more drugs with a different mechanism of pharmacological action and aimed at different biological targets involved in the pathogenesis of the disease.

"Pharmaceutical composition" means a composition comprising a drug substance (substance) and at least one of the components selected from the group consisting of pharmaceutically acceptable and pharmacologically compatible excipients, solvents, diluents, carriers, excipients, distributing and perceiving agents delivery vehicles such as preservatives, stabilizers, fillers, grinders, moisturizers, emulsifiers, suspending agents, thickeners, sweeteners, perfumes, flavors, an ibakterialnye agents, fungicides, lubricants, and prolonged delivery controllers, the choice and suitable proportions of which depend on the nature and purpose of the method and dosage. Examples of suspending agents are ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, as well as mixtures of these substances. Protection against the action of microorganisms can be achieved using a variety of antibacterial and antifungal agents, for example, such as parabens, chlorobutanol, sorbic acid and the like. The composition may also include isotonic agents, for example, sugars, sodium chloride and the like. The prolonged action of the composition can be achieved using agents that slow down the absorption of the active principle, for example aluminum monostearate and gelatin. Examples of suitable carriers, solvents, diluents and delivery vehicles are water, ethanol, polyalcohols, and also mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate). Examples of excipients are lactose, milk sugar, sodium citrate, calcium carbonate, calcium phosphate and the like. Examples of grinders and distributors are starch, alginic acid and its salts, silicates. Examples of lubricants are magnesium stearate, sodium lauryl sulfate, talc, and high molecular weight polyethylene glycol. The pharmaceutical composition for oral, sublingual, transdermal, intramuscular, intravenous, subcutaneous, local or rectal administration of the active principle, alone or in combination with another active principle, can be administered to animals and humans in a standard administration form, in the form of a mixture with traditional pharmaceutical carriers. Suitable unit dosage forms include oral forms such as tablets, gelatine capsules, pills, powders, granules, chewing gums and oral solutions or suspensions, for example a therapeutic shake, sublingual and buccal administration forms, aerosols, implants, topical, transdermal, subcutaneous, intramuscular , intravenous, intranasal or intraocular administration forms and rectal administration forms.

“Pharmaceutically acceptable salt” means the relatively non-toxic organic and inorganic salts of the acids and bases of the present invention. These salts can be obtained in situ during the synthesis, isolation or purification of the compounds or prepared specially. In particular, base salts can be prepared on the basis of the purified free base of the claimed compound and a suitable organic or inorganic acid. Examples of salts thus obtained are hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valeriates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, tosylates, citrates, maleates, fumarates, succinates, tartrates mesylates, malonates, salicylates, propionates, ethanesulfonates, benzenesulfonates, sulfamates and the like. (A detailed description of the properties of such salts is given in Berge S. M., et al., "Pharmaceutical Salts" J. Pharm. Sci. 1977, 66: 1-19). Salts of the claimed acids can also be specially prepared by reacting the purified acid with a suitable base, and metal and amine salts can be synthesized. Metal salts include sodium, potassium, calcium, barium, zinc, magnesium, lithium and aluminum salts, the most desirable of which are sodium and potassium salts. Suitable inorganic bases from which metal salts can be obtained are hydroxide, carbonate, sodium bicarbonate and hydride, potassium hydroxide and bicarbonate, potash, lithium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide. As organic bases from which salts of the claimed acids can be obtained, amines and amino acids are selected that are sufficiently basic to form a stable salt and are suitable for medical use (in particular, they should have low toxicity). Such amines include ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, benzylamine, dibenzylamine, dicyclohexylamine, piperazine, ethylpiperidine, tris (hydroxymethyl) aminomethane and the like. In addition, tetraalkylammonium hydroxides, for example, such as choline, tetramethylammonium, tetraethylammonium and the like, can be used for salt formation. As amino acids, the main amino acids can be used - lysine, ornithine and arginine.

The purpose of this invention is to create a new tool, biologically active additives, pharmaceutical compositions and drugs that have anti-hangover effects and are able to weaken the alcohol hangover caused by excessive consumption of products containing ethyl alcohol.

This goal is achieved by a means of a mixture of serine, tianin and fructose or their pharmaceutically acceptable salts and / or hydrates.

A preferred agent is a mixture of L-serine, L-thianine and fructose or their pharmaceutically acceptable salts and / or hydrates.

A preferred agent is a mixture of L-serine, L-thianine and fructose or their pharmaceutically acceptable salts in a weight ratio of (12-18): (0.8-1.2) :( 40-60), respectively.

Most preferred is an agent that is a mixture of L-serine, L-thianine and fructose or their pharmaceutically acceptable salts in a weight ratio of 15: 1: 50, respectively.

The subject of this invention is also a biologically active anti-hangover supplement containing a new agent, which is a mixture of serine, tianin and fructose or their pharmaceutically acceptable salts and / or hydrates.

A more preferred dietary supplement contains an agent that is a mixture of L-serine, L-thianine and fructose or their pharmaceutically acceptable salts in a weight ratio of (12-18): (0.8-1.2) :( 40-60), respectively, including in a weight ratio of 15: 1: 50.

A dietary supplement may include diluents, auxiliary agents and / or carriers. A dietary supplement along with the agent of the present invention may include other active agents and / or dietary supplements, provided that they do not cause undesirable effects, for example, allergic reactions.

The aim of the present invention is also a method for producing biologically active additives.

This goal is achieved by mixing a new tool of the present invention with an inert filler and / or solvent.

The subject of this invention is also a pharmaceutical composition having an anti-hangover effect, containing a new agent, which is a mixture of serine, tianin and fructose or their pharmaceutically acceptable salts and / or hydrates.

A more preferred pharmaceutical composition contains an agent that is a mixture of L-serine, L-thianine and fructose or their pharmaceutically acceptable salts in a weight ratio of (12-18) :( 0.8-1.2) :( 40-60), respectively , including in a weight ratio of 15: 1: 50.

The pharmaceutical composition may include pharmaceutically acceptable excipients. By pharmaceutically acceptable excipients are meant diluents, excipients and / or carriers used in the pharmaceutical field. The pharmaceutical composition along with the agent of the present invention may include other active agents, provided that they do not cause undesirable effects, for example, allergic reactions.

When using the pharmaceutical composition of the present invention for the manufacture of a medicament, it may include traditional pharmaceutical carriers. Carriers which are used in the pharmaceutical field to produce oral forms of a medicinal product are binders, lubricants, disintegrants, solvents, diluents, stabilizers, suspending agents, colorless agents, flavoring agents; antiseptic agents, solubilizers, stabilizers are used in injection forms of the drug; in local forms of the drug, bases, diluents, lubricants, antiseptic agents are used.

The aim of the present invention is also a method for producing a pharmaceutical composition.

The goal is achieved by mixing the means of the present invention with an inert filler and / or solvent.

A subject of the present invention is also a medicine in the form of tablets, capsules or injections, placed in a pharmaceutically acceptable package, comprising an agent or a new pharmaceutical composition intended to alleviate an alcoholic hangover caused by excessive consumption of products containing ethyl alcohol.

The drug may be administered orally or parenterally (e.g., intravenously, subcutaneously or intraperitoneally). The clinical dosage can be adjusted depending on: therapeutic efficacy and bioavailability of the active ingredients in the body, their metabolic rate and excretion from the body, and also depending on the patient’s age, gender and stage of illness. In accordance with the instructions of a doctor or pharmacist, these drugs can be taken several times during certain periods of time (preferably from one to six times).

The invention is illustrated by graphs which show:

figure 1 - the effect of 25% ethyl alcohol on locomotor activity (time spent in the center and in the sleeves of the closed cruciform labyrinth until the mice made 12 visits to the sleeves) of male SHK mice when a dose of 4.5 g / kg was administered to them inside 1.5 or 3 hours before the test. * - difference from the group receiving placebo (sterile water);

figure 2 - the influence of 25% ethanol on the effectiveness of the research behavior of male SHK mice when they injected inside a dose of 4.5 g / kg 1.5 or 3 hours before the test, evaluated by the behavior of the "patrol" (by the number of visits to the closed hoses the cross-shaped labyrinth until the mice complete the first complete detour of all the sleeves in which they visited at least 1 time). * - difference from the group receiving placebo (sterile water);

figure 3 - the effect of 25% ethyl alcohol on the retention time of male SHK mice on a rotating rod when they introduced a dose of 4.5 g / kg 3 hours before the test, (initial rotation speed 5 rpm, acceleration 0.5 rpm / min every 10 seconds).

* - difference from the group receiving placebo (sterile water);

figure 4 - the effect of 25% ethyl alcohol on prepulse inhibition of trembling in response to an acoustic stimulus, when a dose of 4.5 g / kg was administered to male SHK mice 3 hours before the test. * - difference from the placebo group (sterile water).

The following are specific examples that illustrate but do not limit its scope.

Example 1. The study of the effectiveness of anti-hangover and the ability to weaken the alcohol hangover of a new drug and a drug based on it was carried out in comparison with the reference drug (dimercaprol) in experiments on male SHK mice.

A. The subnarcotic dose of alcohol was determined when administered orally (per os), using a probe, in the form of a 25% solution of ethyl alcohol, which turned out to be 4.5 g / kg for the used mouse line and the period of termination of acute intoxication (intoxication), which started about 3 hours after the introduction of alcohol. In each group, 10 SHK mice were used.

Assessment of acute alcohol intoxication (intoxication) was carried out on mice in a test of spontaneous orientation (patrolling behavior) in a closed cruciform labyrinth (installation of the Open Science company, Russia). The mouse was placed in the central compartment of the labyrinth and, in a semi-automatic mode, the sequence of its transitions from one sleeve to the other was recorded. The test ended when 12 such transitions occurred [Maysky A.I., Salimov P.M. Guidelines for preclinical evaluation of drugs for the treatment of alcoholism. Guidance on the experimental (preclinical) evaluation of new drugs. M .: Remedium, 2000, p. 172-175].

With the introduction of this dose of alcohol, symptoms of acute alcohol intoxication (intoxication) in the form of decreased motor activity and the effectiveness of the research behavior of “patrolling” were present 1 hour after the introduction of alcohol, which was not observed 3 hours after the introduction of alcohol (Figs. 1, 2). At the same time, in the period 3 hours after the introduction of alcohol, such typical objective manifestations of a hangover syndrome were noted as a decrease in the degree of prepulse inhibition and retention time on a rotating rod (Figs. 3, 4).

B. A study of the effect of the new agent on hangover indicators in mice was carried out in comparison with the closest competitor, the well-known drug dimercaprol in a therapeutic dose of 4.2 mg / kg. The mice were injected with a sub-drug dose of alcohol of 4.5 g / kg in the form of a 25% solution of ethyl alcohol using a probe inside (per os) 3 hours before the tests used. Dimercaprol, serine, tianin, fructose and mixtures of serine, tianin and fructose were administered orally 2.5 hours after the introduction of alcohol. In each group, 10 SHK mice were used. We used tests of prepulse inhibition of jerking in response to an acoustic stimulus at the Responder-X installation of Columbus Instruments, USA (braking of the amplitude of jerking to an acoustic stimulus of 10 kHz with a duration of 50 ms and a volume of 105 dB with a similar acoustic stimulus of 85 dB in 100 ms ) and the test of retention on a rotating rod at the Rotamex-5 installation of Columbus Instruments, USA (initial rotation speed of 5 rpm, acceleration of 0.5 rpm every 10 seconds).

The table shows the test data on the effect of funds on hangover indicators in mice 2.5 hours after the administration of 4500 mg / g of alcohol to male SHK mice. The hangover impaired inhibition of trembling by an acoustic stimulus was estimated in%. The hangover of coordination of mouse movements was evaluated by the duration of retention on a rotating rod.

Table. Test results of the effect of funds on hangover rates in mice 2.5 hours after the introduction of alcohol to male SHK mice. No. Tool Components Dose mg / kg Prepulse Inhibition (%) Time to fall from a rotating rod (seconds) one Alcohol 4500 fourteen 38 2 Placebo 38 146 3 Unitiol 4.2 32 95 four L-Tianin 10 44 52 5 L-Serine 150 37 43 6 Fructose 500 38 8 7 L-Tianin
Fructose 10 fifty 77 500 8 L-Tianin 10 36 84 L-Serine 150 9 L-Serine 150 39 122 L-Tianin 10 Fructose 500 10 L-Serine 150 38 110 L-Tianin 8 Fructose 400 eleven L-Serine 150 35 120 L-Tianin 12 Fructose 600 12 L-Serine 180 37 116 L-Tianin 10 Fructose 500 13 Serine 120 34 117 Tianin 10 Fructose 500 fourteen L-Serine 150 36 28 L-Tianin 10 Fructose 200 fifteen L-Serine 3 38 19 L-Tianin 150 Fructose 500

The data presented in the table indicate that the tool according to this invention (No. 9-No. 13) objectively weaken the recorded symptoms of an alcoholic hangover - improve muscle coordination and filtering of sensory information. Thus, a hangover inhibition of the inhibition of trembling by an acoustic stimulus is approximately 2.5 times higher for the investigated substances and placebo (32-38%) compared with alcohol without substances (14%). The hangover of the coordination of movements of mice was evaluated by the duration of the retention of animals on a rotating rod.

The data obtained indicate the greatest efficiency (retention time 117-122 seconds) of the new product (No. 9-No. 13), which is a mixture of serine, tianine and fructose in a weight ratio of (12-18) :( 0.8-1.2) : (40-60). Deviation of the ratio of components in the tool from the claimed in this invention (No. 1 and No. 15) leads to a dramatic reduction in the retention time of animals (19-28 seconds) on a rotating rod.

In addition, the new drug, composition and drug based on it are more preferable compared to the known drug dimercaprol, because they do not have contraindications (liver function insufficiency and hypertension, especially when dimercaprol is used in combination with alcohol), characteristic of the latter [Register medicines. Dimercaprol, http: //www.rlsnetWmnnjdimerkaprol.html; U.S. Department of Health & Human Services. Dimercaprol, http://www.remm.nlm.gov/dimercaprol.htm. Gorelick, P.B. Alcohol and stroke. Stroke. 18: 268-271; 1987; Tirapelli, C. R .; Leone, A.F .; Coelho, E. B. .; Resstel, L.B .; Correa, F.M .; Lanchote, V.L .; Uyemura, S.A .; Padovan, C. M .; de Oliveira, A.M. Effect of ethanol consumption on blood pressure and rat mesenteric arterial bed, aorta and carotid responsiveness. J. Pharm. Pharmacol. 59: 985-993; 2007; Zhang, Y .; Venugopal, S.K .; He, S .; Liu, P .; Wu, J .; Zern, M.A. Ethanol induces apoptosis in hepatocytes by a pathway involving novel protein kinase C isoforms. Cell Signal. 19: 2339-2350; 2007].

Example 2. Obtaining biologically active additives. Thoroughly mix L-serine, L-tianine and fructose in a weight ratio of 15: 1: 50. The resulting powdery mixture is packaged in 300 mg in a suitable size gelatin capsule.

Example 3. Obtaining a drug in the form of tablets. 1600 mg of starch, 1600 mg of crushed lactose, 400 mg of talc and 1000 mg of a mixture of L-serine, L-thianine and fructose are mixed in a weight ratio of 15: 1: 50 and pressed into a block. The resulting bar is crushed into granules and sieved through sieves, collecting granules with a size of 14-16 mesh. The granules obtained are tabletted into a suitable tablet form weighing 560 mg each.

The compounds used in the description and claims are available and manufactured by various companies (www.sigma-aldrich.com).

Claims (6)

1. An agent with anti-hangover action, containing L-serine and fructose as active components, characterized in that it additionally contains tianine, with a mass ratio of L-serine, tianine and fructose (12-18) :( 0.8-1, 2) :( 40-60), respectively. 2. The tool according to claim 1, containing as active components L-serine, L-tianine and fructose in a mass ratio of 15: 1: 50, respectively. 3. The tool according to any one of paragraphs.1 and 2 as a biological additive in food. 4. A pharmaceutical composition having an anti-hangover effect, containing the agent according to any one of claims 1 to 3 and an inert excipient and / or solvent. 5. The method of obtaining the pharmaceutical composition according to claim 4 by mixing the composition according to any one of claims 1 to 3 with an inert filler and / or solvent. 6. A drug having an anti-hangover effect, in the form of tablets, capsules or injections, placed in a pharmaceutically acceptable package, comprising the agent according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4.

Images